28 June 2021 | News
The new APAC Business Development Manager Andy Hu says the main drivers for Asian biotechs looking to Australia are speed, data quality and access to international regulatory authorities
Caption: Andy Hu, APAC Business Development Manager, Avance Clinical, Austalia
Avance Clinical, the leading Australian CRO for international biotechs announced the appointment of Andy Hu as Business Development Manager APAC, to support increasing biotech clinical trial demand from the region.
Formerly with Informa Pharma Intelligence, the international biopharma data company, Andy will head up the APAC business development program for Avance Clinical.
"The main drivers for Asian biotechs looking to Australia are speed, data quality and access to international regulatory authorities. They select Avance Clinical in Australia because its CRO data is accepted by the FDA, and it gives them a rapid pathway for international licensing, investment and ultimately drug approvals. I wanted to work with Avance Clinical because it's a mid-sized CRO that offers deep therapeutic experience, expedited timelines, and exceptional support to APAC biotech clients" he said.
"Andy is multilingual, being fluent in English, Mandarin and Korean, and has completed both a Bachelor of Korean Language and Culture as well as a Master of Translation and Interpreting. He will be responsible for developing business across the APAC region to better serve our clients operating in the region," said Chief Strategy Officer Ben Edwards.